CE
Emergo Europe, Westervoortsedijk 60, 6827 AT Arnhem, The Netherlands
EC REP

Anti-Cytokeratin 19

Clone	Species	Ig Class
RCK108	Mouse	IgG1, kappa

Catalog No.	Description
	Manual
AM246-5M	6 ml of Ready-to-Use Antibody for use with BioGenex Super Sensitive™ Detection Systems
VM246-5M	6 ml of Ready-to-Use Plus Antibody
	Concentrated
MU246-UC	1 ml of Concentrated Antibody for use with BioGenex Super Sensitive™ Detection Systems
MU246-5UC	0.5 ml of Concentrated Antibody for use with BioGenex Super Sensitive™ Detection Systems
	Automation
AM246-10M	10 ml of Ready-to-Use Antibody in a barcode labeled vial for use with BioGenex Super Sensitive™ Detection Systems and i6000™ Automated Staining Systems
AX246-YCD	Ready-to-Use Antibody in Barcode labeled vial for use on the Xmatrx ®Elite Staining System, 160 tests
AX246-50D	Ready-to-Use Antibody in Barcode labeled vial for use on the Xmatrx ®Elite Staining System, 50 tests
AX246-4M	Ready-to-Use Antibody in Barcode labeled Vial for use on the NanoVip™ Staining System, 50 tests
AX246-10M	Ready-to-Use Antibody in Barcode labeled Vial for use on the NanoVip™ 300 Staining System, 100 tests

Recommended Detection Kits:
https://biogenex.com/ihc-detection-kits/

Antibody Incubation: 30-60 Min at RT

Control Tissue: Colon Carcinoma as available with Biogenex FB-246M* & FG-246M*
Recommended Dilution for Concentrated Antibody: 1:100 - 200 in HK156
Recommended Pretreatment: EZ-AR2 (HK522-XAK)

Intended Use

For In Vitro Diagnostic Use. This antibody is designed for the specific localization of human Cytokeratin 19 in formalin-fixed, paraffin-embedded (FFPE) tissue sections. Evaluation must be performed by a qualified pathologist.

Summary and Explanation

Cytokeratin 19 (CK19), a 40 kDa intermediate filament protein, is a marker of simple epithelial cells and is widely expressed in various tissues. CK19 is detected in mesothelial cells, ovarian cysts, cystadenomas, ovarian carcinomas, adenocarcinomas of the lung, and tumor cells within pulmonary metastases. It is also present in the ductal cells of both normal and neoplastic pancreas, and in the basal layer of non-keratinizing stratified squamous epithelia, including the oral cavity and ectocervix. The RCK108 antibody to CK19 identifies a broad spectrum of epithelial cell types, particularly within ductal and glandular structures. CK19 expression is utilized in the characterization and diagnosis of carcinomas, and its presence may correlate with tumor progression, metastatic potential, and patient prognosis in several epithelial malignancies.

Storage and Handling

Store at 2–8°C. Prepare fresh dilutions before use. Diluted solutions are stable for one day at room temperature and can be stored at 2–8°C or –20°C for longer periods. Avoid repeated freeze-thaw cycles.

Principles of the Procedure

IHC involves binding of a primary antibody to a target antigen, followed by visualization using a chromogenic detection system. The procedure can be manual or automated. Include appropriate positive and negative controls in each run.

Reagents Provided

Mouse Monoclonal Antibody to human Cytokeratin 19 is affinity purified and diluted in PBS, pH 7.2, containing 1% BSA and 0.09% sodium azide.

Precautions

Contains <0.1% sodium azide. Follow standard safety protocols. Wear appropriate PPE, avoid skin and mucous membrane contact, and do not pipette by mouth. Dispose of reagents per regulatory guidelines. SDS available on request.

Quality Control

Refer to BioGenex Detection System documentation for guidance on quality control, including recommended positive and negative controls.

Troubleshooting

For detection-related issues, consult the BioGenex Detection System documentation. For assistance, contact BioGenex Technical Support at 1-800-421-4149 or support@biogenex.com, or reach out to your local distributor.

Expected Results

This antibody shows cytoplasmic staining in positive cells in FFPE tissues. Refer to the BioGenex website for representative images. Result interpretation is the user's responsibility and should be confirmed with established diagnostic methods.

Limitations of the Procedure

1. Staining results may vary due to improper tissue processing, fixation, or tissue variability. Endogenous enzymes or biotin may cause non-specific staining. HBsAg-positive tissues may yield false positives with HRP systems. Poor counterstaining or mounting can affect interpretation.
2. Please choose the appropriate catalogs as per the Instrument, as per the Automation/ Manual staining process and as per the user validated protocols.

Bibliography:

1. Versnel MA, Hoogsteden HC, Hagemeijer A, et al. Characterization of three human malignant mesothelioma

USA -48810 Kato Road, Suite 100E & 200E, Fremont, CA 94538, Tel: +1 (800) 421-4149, Fax: +1 (510) 824-1490, support@biogenex.com, www.biogenex.com.
INDIA - Special Economic Zone, Adibatla, Telangana state, Hyderabad, India , 501510.

cell lines. Cancer Genet Cytogenet. 1989;42(1):115-128. DOI: https://doi.org/10.1016/0165-4608(89)90014-9
2. van Niekerk CC, Boerman OC, Ramaekers FC, Poels LG. Marker profile of different phases in the transition of normal human ovarian epithelium to ovarian carcinomas. Am J Pathol. 1991;138(2):455-463. PMCID: PMC1886195
3. Mittal KR, Demopoulos RI, Goswami S. Patterns of keratin 19 expression in normal, metaplastic, condylomatous, atrophic, dysplastic, and malignant cervical squamous epithelium. Am J Clin Pathol. 1992;98(4):419-423. DOI: 10.1093/ajcp/98.4.419
4. Chen Q, Ge F, Cui W, et al. Lung cancer circulating tumor cells isolated by the EpCAM-independent enrichment strategy correlate with Cytokeratin 19-derived CYFRA21-1 and pathological staging. Clin Chim Acta. 2013;419:57-61. DOI: 10.1016/j.cca.2013.01.015
5. Yoneda N, Sato Y, Kitao A, et al. Epidermal growth factor induces cytokeratin 19 expression accompanied by increased growth abilities in human hepatocellular carcinoma. Lab Invest. 2011;91(2):262-272. DOI: 10.1038/labinvest.2010.161
6. Omata M, Liew CT, Ashcavai M, Peters RL. Nonimmunologic binding of horseradish peroxidase to hepatitis B surface antigen. A possible source of error in immunohistochemistry. Am J Clin Pathol. 1980;73(5):626-632. DOI: 10.1093/ajcp/73.5.626
7. Centers for Disease Control. Control Manual Guide--Safety Management. CDC-22. Atlanta, GA: Centers for Disease Control; April 30, 1976. Available at: http://medbox.iiab.me/modules/en-cdc/www.cdc.gov/niosh/docs/78-127/78127_13.html.

	Temperature Limitation		In Vitro Diagnostic Medical Device
	Use By Date		Batch Code
	Non-Sterile		Consult Instructions for Use
	Representative in the European Community		Manufacturer

© 2020, BioGenex Laboratories. All rights reserved.